Jemec GBE, et al. - In phase 3, randomized, placebo-controlled, PIONEER trials, investigators estimated the data to evaluate the optimal medium-term adalimumab maintenance dosing strategy in moderate-to-severe hidradenitis suppurativa (HS). They randomized the candidates to adalimumab 40 mg every-week (ADAew) (Period A) and then, re-randomized in Period B to ADAew (ADAew/ew), ADA every-other-week (ADAew/eow), or placebo (ADAew/pbo). They observed the HiSCR week-36 rate, 48·1% (ADAew/ew) vs 46·2% (ADAew/eow) and 32·1% (ADAew/pbo) for week-12 HiSCR achievers. They reported better outcomes in partial response after 12 weeks with continued weekly dosing than dose reduction or interruption, with no remarkable differences in safety profile.